Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

Summary

Anxiety disorders are challenging to treat and typically diagnosed based on symptoms rather than biological markers. Research in New Zealand has led to the development of an EEG biomarker for anxiety that may identify cases resistant to standard treatments. Additionally, ketamine has been found effective for treatment-resistant neurotic disorders. This work, alongside similar findings with other psychedelics, suggests promising new avenues for faster and more effective treatments.

Study at a glance

Abstract

The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the University of Otago, we have developed an anxiety disorder biomarker and shown its potential to detect anxiety resistant to conventional treatments. Others have started similar work on depression biomarkers. We have also found that ketamine is a novel treatment for treatment-resistant neurotic disorders in general and have provided a "double hit" hypothesis of the mechanisms involved. Muthukumaraswamy and coworkers at the University of Auckland and elsewhere have obtained similar results with ketamine, LSD, and psilocybin, and we, along with them, have demonstrated treatment-related effects on EEG. These linked developments, potentially supplemented with psychotherapy, should open the way to quicker acting, broad ranging, effective treatment of neurotic disorders. With the our recent more purely practical development of oral tablet delivery, which will allow home dosing, the future for the treatment of neurotic disorders looks bright.

Tags